CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
LAP-BAND® Adjustable Gastric Band (LAGB®)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00580502
NCT00580502Phase 3Completed
CompareCT.gov

A Prospective Study to Evaluate the Safety and Efficacy of LAP-BAND® Adjustable Gastric Band (LAGB®) Operations for Patients With BMI Between 30-40 kg/m2 With Co-morbidities

NYU Langone Health·interventional·Posted Dec 24, 2007·Updated Mar 23, 2015

In Brief

A Phase 3 clinical trial evaluating LAP-BAND® Adjustable Gastric Band (LAGB®) for Obesity. Completed, enrolled 50 participants.

Detailed Summary

This study is to evaluate the safety and efficacy of Gastric Banding for patients with body mass index (BMI) between 30-40 kg/m2 with medical conditions related to obesity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
Countries--
CollaboratorsAllergan

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 24, 2007
Enrollment StartMar 1, 2004
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 18.5 years ago

Interventions

LAP-BAND® Adjustable Gastric Band (LAGB®)device

Bariatric surgery for patient whose BMI is between 30 and 40 kg/m\^2